To the Editor We read with interest the article “Cetuximab and Radiotherapy in Laryngeal Preservation for Cancers of the Larynx and Hypopharynx: A Secondary Analysis of a Randomized Clinical Trial” by Bonner et al.1 We congratulate the authors on their phase 3 clinical trial, however, some potentially misleading ambiguities can be noticed in their article.
D’Ascanio L, Ricci G, Piazza F. Cetuximab and Radiotherapy in Laryngeal Preservation. JAMA Otolaryngol Head Neck Surg. 2017;143(5):525–526. doi:10.1001/jamaoto.2016.3821
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: